Brightsurf Science News & Current Events

September 26, 2015
A large real-life study shows trabectedin confers long-term efficacy in STS
A prospective, large real-life study with an investigational transcription inhibitor confers long term-efficacy in patients with soft tissue sarcoma.

Rare cancer responds unusually well to new treatment
Results from a multi-center randomized international trial of an innovative treatment show a marked improvement in the length of time patients with mid-gut neuroendocrine tumors live without the disease getting worse.

Lung cancer survival rates improve with CT scan follow-up
Patients with recurrent lung cancer have better post-surgery survival rates if their management includes a follow-up program based on computer tomography of the chest, according to new findings.

Six new countries in ESMO Designated Centres of Integrated Oncology and Palliative Care
Patient eligibility for opioids is seriously restricted in some countries, with the highest rate of limited access to palliative care found in the Middle East, followed by Latin America and the Caribbean and Asia.

Treatment of elderly breast cancer patients varies between different European countries
Largest international comparison of the treatment of elderly patients with breast cancer have shown there are substantial differences in the use of surgery, hormone therapy and chemotherapy between European countries.

Differences between tumors of younger and older colorectal cancer patients
Tumors in younger colorectal cancer patients may be molecularly distinct from those of older patients, and that these differences are related to the way genes are switched on and off (epigenetics) in the tumors of the younger patients and may lead to better treatment options.

The Lancet Oncology: Tackling the global shortfall in radiotherapy could save millions of lives and boost the economy of poorer countries
Millions of people are dying from potentially treatable cancers like breast and prostate because of a chronic underinvestment in radiotherapy resources, according to a major new Commission on access to radiotherapy, published in The Lancet Oncology, and being presented at the 2015 European Cancer Congress in Vienna, Austria.

Migrants and refugees: Nationality and social status affect cancer care quality
Access to quality cancer care is still a big issue in Europe, and there is great heterogeneity in the availability of drugs, screening programs and resources among countries.

Childhood cancers in Europe: Progress has been made, but much remains to be done
Each year in Europe, 6,000 young people die from cancer, and two-thirds of those who survive suffer from treatment-related side effects.

Results of international trial show promise in rare, difficult to treat cancer
An international team of researchers has shown that the use of the mTOR inhibitor, everolimus, can delay tumour growth among both gastrointestinal and lung neuroendocrine tumours.

Genetic screening of brain metastases could reveal new targets for treatment
Unravelling the genetic sequences of cancer that has spread to the brain could offer unexpected targets for effective treatment.

Genetic profiles of brain metastases differ from those of primary tumors
A new study finds that, while brain metastases share some genetic characteristics with the primary tumors from which they originated, they also carry unique genetic mutations, indicating that the evolutionary pathways of the metastatic and the primary tumors have diverged, which may change sensitivities to targeted therapy drugs.

Everolimus improves progression-free survival for patients with advanced, nonfuctional neuroendocrine tumors
In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin, has shown to dramatically improve progression-free survival for patients with advanced, nonfunctional neuroendocrine tumors of the lung and gastrointestinal tract.

Impact of hearing loss and treatment options at various ages
Hearing loss, estimated to affect upwards of 48 million people in the United States, will be a hot topic among new research presented at the 2015 Annual Meeting & OTO EXPO of the American Academy of Otolaryngology--Head and Neck Surgery Foundation (AAO-HNSF) in Dallas.
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.